Kidist K. Yimam

Mar 29, 2023 | emjreviews.com | Cynthia Levy |Gideon Hirschfield |Andreas Kremer |Kidist K. Yimam

Itch TreatmentItch progressed in intensity (NRS: 8−9/10) and how much it affected the patient’s QoL. There was no benefit from antihistamines and an anion-exchange resin was not tolerated due to the unpleasant taste, so it was terminated by the patient. Rifampicin was not prescribed due to drug-drug interactions with oral contraceptives, which the patient wished to remain taking, and a fibrate brought mild benefit but was not tolerated due to myopathy.